MedTrace Logo

Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints

NCT02349607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-04-23

No results posted yet for this study

Summary

This study will examine the activity of PF-05089771 and pregabalin, alone and in combination on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects

Conditions

  • Healthy

Interventions

DRUG

PF-05089771 300mg

PF-05089771 300 mg

DRUG

PF-05089771 300 mg + pregabalin 300 mg

PF-05089771 300 mg + pregabalin 300 mg

DRUG

Placebo

Placeco

DRUG

pregabalin 300 mg

pregabalin 300 mg

DRUG

ibuprofen 600 mg

ibuprofen 600 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02349607 on ClinicalTrials.gov